Trial · NCT02979093
Oxytocin and Brain Responses in Maternal Addiction
NCT02979093, Phase 2, Terminated, Lane Strathearn, MBBS PhD; results first posted 2025-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oxytocin and Brain Responses in Maternal Addiction. Trials, record NCT02979093. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02979093
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oxytocin and Brain Responses in Maternal Addiction
- NCT number
- NCT02979093
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 59 participants, actual
- Lead sponsor
- Lane Strathearn, MBBS PhD
- Conditions
- Maternal Behavior, Maternal Addiction
- Interventions
- Oxytocin, Placebos, Functional MRI scanning
- First posted
- 2016-12-01
- Last updated
- 2025-03-26
- Results first posted
- 2025-03-26
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | 50 minutes after administration of oxytocin or placebo | Brain activation (blood-oxygen level dependent \[BOLD\] signal) in response to reward-related cues (own \[O\] vs. unknown \[U\] infant happy faces). Brain activation (BOLD signal) in response to stress-related cues (own \[O\] vs. unknown \[U\] infant sad faces). Specific regions of interests include the striatum and amygdala (for both happy and sad faces). |
| Primary | Effect of Intranasal Oxytocin on Brain fMRI Activation in Addicted vs Controls Mothers (Hypotheses 1 and 2B) | 50 minutes after administration of oxytocin or placebo | Brain activation (BOLD signal) in response to reward-related cues (own \[O\] vs. unknown \[U\] infant happy faces). Specific region of interest includes the ventromedial prefrontal cortex (vmPFC) (interaction effect). Brain activation (BOLD signal) in response to stress-related cues (own vs. unknown infant sad faces). Specific region of interest includes the dorsolateral prefrontal cortex (dlPFC) (interaction effect). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | 50 minutes after administration of oxytocin or placebo | Sample consists of both mothers with addiction and mothers who have no history of addiction, with one or two scanning sessions. Individuals with movement artifact or preprocessing problems removed. As pre-specified in the study protocol and similar to most functional MRI studies, the contrasts between two stimuli are reported (e.g., own vs unknown baby faces). | BOLD signal | LEAST_SQUARES_MEAN |
| PRIMARY | Effect of Intranasal Oxytocin on Brain fMRI Activation in Addicted vs Controls Mothers (Hypotheses 1 and 2B) | 50 minutes after administration of oxytocin or placebo | The fMRI data was obtained from 43 participant mothers (21 in the Addiction group and 22 in the Control group), each of whom provided one or two valid scanning session, totaling 74 sessions. Of the 21 Addiction mothers, 15 contributed scanning data in the Oxytocin condition, and 19 in the Placebo condition. Of the 22 Control mothers, 19 contributed data in the Oxytocin condition, and 21 in the Placebo condition. As pre-specified in the protocol, the contrasts between two stimuli are reported. | BOLD signal | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Oxytocin | Happy faces (O>U): Striatum | -.33 | Standard Error .16 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Placebo | Happy faces (O>U): Striatum | .00678 | Standard Error .14 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Oxytocin | Happy faces (O>U): Amygdala | -.25 | Standard Error .16 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Placebo | Happy faces (O>U): Amygdala | .16 | Standard Error .15 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Oxytocin | Sad faces (O>U): Striatum | .34 | Standard Error .14 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Placebo | Sad faces (O>U): Striatum | .04 | Standard Error .13 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Oxytocin | Sad faces (O>U): Amygdala | .36 | Standard Error .14 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation, Independent of Addiction Status (Hypotheses 1 and 2A). | Placebo | Sad faces (O>U): Amygdala | .04 | Standard Error .13 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation in Addicted vs Controls Mothers (Hypotheses 1 and 2B) | Addicted - Oxytocin Condition | Happy faces (O>U): vmPFC | .00266 | Standard Error 0.20 | BOLD signal |
| Effect of Intranasal Oxytocin on Brain fMRI Activation in Addicted vs Controls Mothers (Hypotheses 1 and 2B) | Control - Oxytocin Condition | Happy faces (O>U): vmPFC | -0.30 | Standard Error 0.18 | BOLD signal |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Scan Session | STARTED | ADDICTION: PLACEBO FIRST GROUP | 12 | 12 |
| First Scan Session | STARTED | ADDICTION: OXYTOCIN FIRST GROUP | 12 | 12 |
| First Scan Session | STARTED | CONTROL: PLACEBO FIRST GROUP | 12 | 12 |
| First Scan Session | STARTED | CONTROL: OXYTOCIN FIRST GROUP | 12 | 12 |
| First Scan Session | COMPLETED | ADDICTION: PLACEBO FIRST GROUP | 11 | 11 |
| First Scan Session | COMPLETED | ADDICTION: OXYTOCIN FIRST GROUP | 10 | 10 |
| First Scan Session | COMPLETED | CONTROL: PLACEBO FIRST GROUP | 10 | 10 |
| First Scan Session | COMPLETED | CONTROL: OXYTOCIN FIRST GROUP | 12 | 12 |
| First Scan Session | NOT COMPLETED | ADDICTION: PLACEBO FIRST GROUP | 1 | 1 |
| First Scan Session | NOT COMPLETED | ADDICTION: OXYTOCIN FIRST GROUP | 2 | 2 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ADDICTION: PLACEBO | 0 | 17 |
| Total, all-cause mortality | ADDICTION: OXYTOCIN | 0 | 17 |
| Total, all-cause mortality | CONTROL: PLACEBO | 0 | 20 |
| Total, all-cause mortality | CONTROL: OXYTOCIN | 0 | 20 |
| Total, other adverse events | ADDICTION: PLACEBO | 0 | 17 |
| Total, other adverse events | ADDICTION: OXYTOCIN | 0 | 17 |
| Total, other adverse events | CONTROL: PLACEBO | 0 | 20 |
| Total, other adverse events | CONTROL: OXYTOCIN | 0 | 20 |
| Total, serious adverse events | ADDICTION: PLACEBO | 0 | 17 |
| Total, serious adverse events | ADDICTION: OXYTOCIN | 0 | 17 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02979093
GET https://conductscience.org/api/trials/v1/NCT02979093/flow?page=2